B+
Bull case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
ELTX
Elicio TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-17
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+49.0
Score
AI commentary
Primary-source tone remains mixed-to-negative: new combination studies and preliminary response observations preserve optionality, but the failed Phase 2 primary endpoint and runway only into Q1 2027 dominate. The packet supplies no sufficient social coverage, verified options skew, short-interest figure, employee score, dependable analyst revisions, or post-event price-reaction attribution; zero values in the sentiment object denote unavailable inputs rather than neutral readings. The deterministic prior is negative across 5- to 120-day horizons, supporting cautious monitoring rather than a rebound thesis.
RankAlpha Sentiment Codex - 2026-09-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventQ4 2026 ELI-002 7P combination-trial initiationHigh impact
Elicio anticipates initiating a Phase 1 study of ELI-002 7P with a RAS small-molecule inhibitor, with or without anti-PD-1 therapy, in metastatic pancreatic cancer during Q4 2026. Initiation could restore clinical optionality after the Phase 2 primary-endpoint miss, but it would not provide efficacy validation. [#PR-EARNINGS-2026-08-13]
2027-03-31catalystFinancing and runway checkpointHigh impact
The July 2026 $15 million financing supports stated runway only into Q1 2027. Absent partnering, reduced spending, or another source of capital, the approaching funding window creates material dilution and development-continuity risk. [#PR-EARNINGS-2026-08-13]
2027-09-17catalystMSK-led neoadjuvant Phase 1 executionHigh impact
The Memorial Sloan Kettering-led Phase 1 study evaluating ELI-002 7P with chemotherapy and checkpoint inhibition has been activated. Enrollment progress and eventual clinical observations could validate the combination strategy, but no results timeline was disclosed. [#PR-EARNINGS-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-17 • Updated nightlySource: Internal modelMethodology